<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

	Т.	
Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide	"##Western blotting" in Methods	
supplier name, catalogue number		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species	"##Cell culture" in Methods	, a
information, strain. Provide	moen culture in methods	
accession number in repository OR		
supplier name, catalog number,		
Primary cultures: Provide species,		n/a (Primary
strain, sex of origin, genetic		cultures are not
modification status.		included in this
mounication status.		study)
		,
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species,		n/a (Experimental
strain, sex, age, genetic modification		animals are not
status. Provide accession number in		included in this
repository OR supplier name, catalog		study)
number, clone number, OR RRID		
Animal observed in or captured		n/a (Experimental
from the field: Provide species, sex		animals are not
and age where possible		included in this
,		study)
Model organisms: Provide		n/a (Experimental
Accession number in repository		animals are not
(where relevant) OR RRID		included in this
(Where relevant) OK KKID		study)
		studyy
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique		n/a (Plants and
accession number if available, and source		microbes are not
(including location for collected wild		included in this
specimens)		study)
Microbes: provide species and		n/a (Plants and
strain, unique accession number if		microbes are not
available, and source		included in this
,		study)
Human recearch narticinante	Yes (indicate where provided: section/paragraph)	n/a
Human research participants Identify authority granting ethics	(maleute where provided, section/paragraph)	n/a (Human
approval (IRB or equivalent committee(s),		research is not
provide reference number for approval.		included in this
production approval.		study)
Provide statement confirming informed		n/a (Human
consent obtained from study		research is not
participants.		included in this
		study)
Report on age and sex for all study		n/a (Human
participants.		research is not
- 1		included in this
		study)

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		n/a (Clinical trials are not included in this study)
Laboratory protocol Provide DOI or other citation details if detailed step-by-step	Yes (indicate where provided: section/paragraph) "##Reverse transcription-quantitative PCR (RT-qPCR)"in Methods	n/a
Experimental study design	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination		n/a (This study does not cover statistic details related to experimental study design)
Randomisation		n/a (This study does not cover statistic details related to experimental study design)
Blinding		n/a (This study does not cover statistic details related to experimental study design)
Inclusion/exclusion criteria		n/a (This study does not cover statistic details related to experimental study design)
Sample definition and in-	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in	"##Statistical analyses" in #Methods	
Define whether data describe technical or biological replicates	"##Statistical analyses" in #Methods	
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent		n/a (Human research is not included in this study)
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide		n/a (Experimental animals are not included in this study)
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		n/a (it is not applicable in this study)
Dual Use Research of Concern If study is subject to dual use research of concern, state the authority granting approval and	Yes (indicate where provided: section/paragraph)	n/a n/a (The study is not subject to DURC)

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the		n/a (The
analysis is excluded, and whether the criteria		information is not
for exclusion were determined and specified		included in this
in advance.		study)
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify	"##Statistical analyses" in Methods	11/4
choice of tests.	##Statistical analyses in Methods	
Data Availability	Voc (indicate subore presided, costion/personal)	-/-
State whether newly created datasets are	Yes (indicate where provided: section/paragraph)	n/a n/a (This study does
available, including protocols for access or		, ,
restriction on access.		not cover newly
	Data Chavina Ctatava ant	created datasets)
If data are publicly available, provide accession number in repository or DOI or	Data Sharing Statement	
If publicly available data are reused, provide		n/a (This study does
accession number in repository or DOI or		not cover reused
URL, where possible.		publicly available
		data)
Code Availability	Voc (indicate subore presided, costion/personal)	n/a
For all newly generated code and software	Yes (indicate where provided: section/paragraph)	n/a
essential for replicating the main findings of		
the study:		
the study.		
State whether the code or software is		n/a/Cada
available.		n/a (Code
available.		availability is not
		included in this

Reporting

If code is publicly available, provide accession

number in repository, or DOI or URL.

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with	·	
the manuscript.		

study)

study)

n/a (Code

availability is not included in this

Article information: https://dx.doi.org/10.21037/jgo-22-672	